Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 16:5:57-62.
doi: 10.1016/j.ijcha.2014.10.007. eCollection 2014 Dec.

Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation

Vassilis Voudris  1 , Panagiotis Karyofyllis  1 , Constantinos Doulaptsis  1 , Ioannis Moukas  1 , Sofia Thomopoulou  1 , Denis V Cokkinos  1
Affiliations

Long-term dual antiplatelet treatment and bleeding complications in diabetic patients treated with drug eluting stent implantation

Vassilis Voudris et al. Int J Cardiol Heart Vasc. .

Abstract

Background: Dual antiplatelet treatment (DAPLT) for at least 12 months is recommended after drug eluting stent (DES) implantation, but concerns regarding the extended use of this treatment persist due to increased risk of bleeding. In this study are assessed the incidence, correlates, and clinical significance of bleeding complications in diabetic patients after long-term DAPLT post DES implantation.

Methods: We studied 610 consecutive diabetic patients after DES implantation. The primary end point was the occurrence of any bleeding according to the BARC and TIMI definitions.

Results: The incidence of overall bleeding was higher in patients on DAPLT (21.1% vs. 4.4%, p < 0.001); minor/minimal according to the TIMI definition, and type 1 or 2 according to the BARC definition, were more frequently observed in patients on DAPLT (20.3% vs. 3.0%, p < 0.001, 15.6% vs. 2.0%, p < 0.001 and 4.4% vs. 0.5%, p = 0.034, respectively), whereas there was no effect on type 3 (3.5% vs. 2.0%, p = ns). DAPLT was an independent predictor for overall (HR 5.35, 95% CI: 2.69-10.67, p < 0.001), minor (HR 7.45, 95% CI: 3.25-17.12, p < 0.001, for TIMI classification) and type 1 or 2 bleeding (HR 8.17, 95% CI 3.29-20.25, p < 0.001); furthermore smoking was also predictor for overall bleeding (HR 1.65, 95% CI: 1.05-2.61, p = 0.030). Cardiovascular adverse events were not more frequent in patients with bleeding as compared with those without bleeding.

Conclusions: Long-term DAPLT in diabetic patients after DES implantation is associated with higher risk of overall and minor but not major bleeding; smoking may have a significant role in the occurrence of bleeding complications.

Keywords: Antiplatelet therapy; Bleeding; Coronary artery disease; Diabetes mellitus; Drug eluting stents.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative bleeding free rates during the follow-up period. Cumulative bleeding-free rate for the first year was 98.0% (SE = 0.6%), for two years 95.3% (SE = 0.9%) and for five years 89.4% (SE = 1.3%).
Fig. 2
Fig. 2
Cumulative hazard of bleeding for patients on DAPLT vs. SAPLT treatment. Patients on DAPLT had greater hazard for bleeding complication. DAPLT: dual antiplatelet treatment, SAPLT: single antiplatelet treatment.
See this image and copyright information in PMC

References

    1. King S.B., Smith S.C., Hirshfeld J.W., Jacobs A.K., Morrison D.A., Williams D.O. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261–295. - PubMed
    1. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782. - PubMed
    1. Moreno P.R., Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293–2300. - PubMed
    1. Scheen A.J., Warzee F., Legrand V.M. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J. 2004;25:2167–2168. - PubMed
    1. Yang T.H., Park S.W., Hong M.K., Park D.W., Park K.M., Kim Y.H. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol. 2005;96:1389–1392. - PubMed

LinkOut - more resources